Oesophageal cancer gene identified

May 9, 2014
Multiple copies of the TRIM44 gene in an oesophageal cancer cell line. Credit: Professor Rebecca Fitzgerald and Dr Johnny Ong

(Medical Xpress)—A newly-discovered gene linked to oesophageal cancer holds the promise of new treatments for this notoriously difficult-to-fight disease.

Researchers believe based on their discovery could help up to 15% of the 8,500 people diagnosed with oesophageal in the UK every year. The study, by scientists from the University of Cambridge, is published in the Journal of the National Cancer Institute.

With the advance of DNA sequencing, researchers are increasingly able to identify genes associated with diseases. Unfortunately, more often than not the function of the gene is unknown, making it difficult to develop a treatment based on the discovery.

The new Cambridge research found not only that the TRIM44 gene plays a key role in the development of but also discovered how the gene drives the disease. The new research reveals that over-expression (when there are multiple copies) of TRIM44 leads to higher activity of the mTOR gene, which regulates cell growth and division - processes that become uncontrolled in cancer.

"We know how effective treatments targeting the over-expression of can be – just look at the success of Herceptin for breast and ," said Professor Rebecca Fitzgerald, lead author of the research from the MRC Cancer Unit at the University of Cambridge. "As there are already a number of drugs which target mTOR, we are hopeful that our discovery could lead to new treatments within the next five years."

The researchers have already found that when they treat tumours in mice which are over-expressing TRIM44 with mTOR inhibitors, they reduced in size. Interestingly, they have also performed the same experiments with cells from human breast cancers, and found the same results, indicating that these findings could also be applied to other cancers.

Professor Fitzgerald added: "For cancer of the oesophagus, and other cancers such as , when the TRIM44 gene is over-expressed, it can also be used to indicate the likely response of an individual to an mTOR inhibitor drug. By tailoring the treatment to the individual, we increase the chance that it will be effective at fighting the disease."

Oesophageal cancer is the ninth commonest cancer in the UK, and the sixth most common cause of cancer death. Many people are unaware of cancer of the oesophagus and symptoms are often ignored. As a result, the disease is frequently at an advanced stage when it is diagnosed. Only around 15% of people diagnosed with oesophageal cancer are alive five years later.

Explore further: Tumour expression of leptin associated with chemotherapy resistance

More information: The paper, "Amplification of triM44: Pairing a Prognostic target With Potential therapeutic Strategy," is available online: jnci.oxfordjournals.org/conten … dju050.full.pdf+html

Related Stories

Tumour expression of leptin associated with chemotherapy resistance

February 26, 2014
Patients with the most common type of oesophageal cancer are less likely to respond to chemotherapy when their tumours are high in a protein called leptin, according to research published in the British Journal of Cancer.

High risk oesophageal cancer gene discovered

January 19, 2012
New research from Queen Mary, University of London has uncovered a gene which plays a key role in the development of oesophageal cancer (cancer of the gullet).

Patients with mouth and oesophageal cancers take longer to seek help from GP

February 11, 2014
People with cancers of the mouth and oesophagus are waiting longer between first noticing a symptom and going to their GPs compared to patients with other types of cancers, according to research published in the International ...

More oesophageal cancer patients benefit from pre-op chemo than previously thought says study

December 23, 2013
More oesophageal cancer patients than previously thought are benefiting from having chemotherapy before an operation to remove their tumour, according to new research published in the World Journal of Gastroenterology.

Genomic testing links 'exceptional' drug response to rare mutations in bladder cancer

March 13, 2014
A patient with advanced bladder cancer in a phase I trial had a complete response for 14 months to a combination of the targeted drugs everolimus and pazopanib, report scientists led by a Dana-Farber Cancer Institute researcher, ...

Deaths from oesophageal cancer up by almost 50 per cent in last 40 years

January 6, 2014
The number of people dying from oesophageal cancer – cancer of the gullet or food pipe – has risen by 49 per cent in the last 40 years according to new figures published by Cancer Research UK, today.

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.